MicroPort CardioFlow Medtech Corporation (2160.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Address
Zhangjiang Hi-Tech Park
Shanghai, 201203
China
Phone
86 21 3895 4600
Sector
Healthcare
Industry
Medical - Devices
Employees
430
First IPO Date
February 04, 2021
| Name | Title | Pay | Year Born |
| Ruinian Zhang | CEO, GM & Executive Director | 1.79M | 1964 |
| Philippe Wanstok | President & Executive Director | 156,743 | 1964 |
| Paul Vodden | Chief Financial Officer | 0 | 1966 |
| Xiaoming Zhu | Chief Operating Officer | 0 | 1968 |
| Alice Flacco | Executive VP & General Counsel | 0 | 1985 |
| Lok Yee Chan | Joint Company Secretary | 0 | 1990 |
| Xiangmei Li | Joint Company Secretary | 0 | N/A |
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.